European Roll Out For Samsung Bioepis's Etanercept Biosimilar
This article was originally published in PharmAsia News
Executive Summary
After gaining two regulatory approvals for its biosimilars at home last year, South Korea's Samsung Bioepis has now received its first overseas clearance for an etanercept biosimilar, in Europe. Benepali, which will be Europe's first biosimilar version of the fusion protein, is set to enter 31 European markets.
You may also be interested in...
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
AIRIS 2024: Global Cooperation A Challenge For Regulation Of AI Products
During the first international symposium on the use of AI in medical products, co-hosted by US and Korean regulators, global experts discussed issues and challenges related to effective development and regulation. Cooperation, flexibility and the need for a "human-centric" approach emerged as key themes in the fast-moving field.